Cargando…

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma

Nivolumab, a programmed death-1 checkpoint inhibitor, is worldwide available for metastatic renal cell carcinoma (mRCC). Limited data exist on the response to vascular endothelial growth factor receptor-tyrosine kinase inhibitor (TKI) therapy after administration of nivolumab. In this case study, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narukawa, Tsukasa, Hongo, Fumiya, Fujihara, Atsuko, Ueno, Akihisa, Matsugasumi, Toru, Ukimura, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154254/ https://www.ncbi.nlm.nih.gov/pubmed/32308585 http://dx.doi.org/10.1159/000506196

Ejemplares similares

Robot‐assisted laparoscopic partial nephrectomy for horseshoe kidney: A case report
por: Fujihara, Atsuko, et al.
Publicado: (2019)

Usefulness of bicarbonate Ringer's solution as perfusate during transurethral resection of the prostate
por: Hongo, Fumiya, et al.
Publicado: (2021)

Double renal cell carcinoma with histological type of clear cell carcinoma and papillary carcinoma in the same kidney concurrently treated with robot‐assisted partial nephrectomy
por: Shimizu, Teruki, et al.
Publicado: (2021)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

Remitting seronegative symmetrical synovitis with pitting edema syndrome in maintenance hemodialysis
por: Matsugasumi, Toru, et al.
Publicado: (2020)

Phase I study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol
por: Yamada, Yasuhiro, et al.
Publicado: (2019)

CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells
por: Ito, Saya, et al.
Publicado: (2018)

Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion
por: Shiraishi, Takumi, et al.
Publicado: (2020)

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study
por: Inoue, Yuta, et al.
Publicado: (2023)

Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case
por: Todo, Maki, et al.
Publicado: (2019)

Prostate squamous cell carcinoma developing 11 years after external radiotherapy for prostate adenocarcinoma
por: Matsugasumi, Toru, et al.
Publicado: (2020)

Robot‐assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction due to aberrant blood vessel with ipsilateral retrocaval ureter
por: Inoue, Yuta, et al.
Publicado: (2021)

A big data-based prediction model for prostate cancer incidence in Japanese men
por: Kato, Mineyuki, et al.
Publicado: (2023)

Increasing rectum–prostate distance using a hydrogel spacer to reduce radiation exposure during proton beam therapy for prostate cancer
por: Narukawa, Tsukasa, et al.
Publicado: (2023)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Gene expression profiles during tissue remodeling following bladder outlet obstruction
por: Ito, Saya, et al.
Publicado: (2021)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
por: Porta, Camillo, et al.
Publicado: (2017)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level
por: Ogura, Ryota, et al.
Publicado: (2023)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

One year survivor of metastatic renal cell carcinoma treated with pazopanib
por: Inn, Fam Xeng, et al.
Publicado: (2017)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
por: Bonadioa, Renata Colombo, et al.
Publicado: (2019)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
por: Kim, Moon Jin, et al.
Publicado: (2016)

Novel device for dividing core needle biopsy specimens to provide paired mirror image-like tissues for genetic and pathological tests
por: Nakamura, Yuichi, et al.
Publicado: (2023)

Challenge and Outcome for the Prostate Squamous Cell Carcinoma Which Developed 8 Years after Low-Dose-Rate Brachytherapy Approached by a Combined Multimodal Treatment with High-Dose-Rate Interstitial Brachytherapy, External Beam Radiation Therapy, and Chemotherapy
por: Matsugasumi, Toru, et al.
Publicado: (2021)

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
por: Matsumura, Soichi, et al.
Publicado: (2023)

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
por: Buti, Sebastiano, et al.
Publicado: (2021)

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
por: Zhang, Tian, et al.
Publicado: (2020)

Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS
por: Outani, Hidetatsu, et al.
Publicado: (2014)

High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kf3s8crke7v1dihgio7d3ptg3f